1. Home
  2. PUBM vs NGEN Comparison

PUBM vs NGEN Comparison

Compare PUBM & NGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PubMatic Inc.

PUBM

PubMatic Inc.

HOLD

Current Price

$9.83

Market Cap

303.6M

Sector

Technology

ML Signal

HOLD

NGEN

NervGen Pharma Corp. Common stock

N/A

Current Price

$3.75

Market Cap

314.8M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
PUBM
NGEN
Founded
2006
2017
Country
United States
Canada
Employees
N/A
9
Industry
Computer Software: Prepackaged Software
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
303.6M
314.8M
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
PUBM
NGEN
Price
$9.83
$3.75
Analyst Decision
Buy
Strong Buy
Analyst Count
7
1
Target Price
$12.43
$18.00
AVG Volume (30 Days)
668.8K
165.5K
Earning Date
05-07-2026
04-02-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$282,926,000.00
N/A
Revenue This Year
$3.44
N/A
Revenue Next Year
$7.86
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.15
$3.51
52 Week High
$13.26
$5.93

Technical Indicators

Market Signals
Indicator
PUBM
NGEN
Relative Strength Index (RSI) 54.51 44.75
Support Level $7.92 $3.59
Resistance Level $9.95 $4.44
Average True Range (ATR) 0.49 0.20
MACD -0.04 -0.00
Stochastic Oscillator 48.41 35.34

Price Performance

Historical Comparison
PUBM
NGEN

About PUBM PubMatic Inc.

PubMatic Inc is a supply-side platform provider in the digital advertising technology market. These platforms help publishers, which supply digital ad inventory, manage their inventory, selling a high percentage of their inventory (increase the ad fill rate) and maximizing revenue per ad sold (optimize yield). The company generates revenue mainly by taking a piece of the ad sales that it enables. Buyers on the platform include intermediary buyers, such as demand-side platforms, or advertisers and ad agencies directly. Geographically, the company generates the majority of its revenue from the United States, followed by EMEA and APAC.

About NGEN NervGen Pharma Corp. Common stock

NervGen Pharma Corp is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other traumatic and neurologic conditions. The Company's principal business activity is the discovery, development and commercialization of neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. NervGen's initial target indication is SCI. The company's pipeline products include NVG-291 and NVG-300.

Share on Social Networks: